Location:
The Kirby Institute Level 6 Seminar Room Wallace Wurth Building UNSW Australia Sydney NSW 2052
Open to
All
Contact for enquiries
Rata Joseph +61 (0)2 9385 0900 rjoseph@kirby.unsw.edu.au
The Kirby Institute is pleased to present:
"Recent Results from the TREAT Asia HIV Observational Databases."
Mr David Boettiger - Statistician- Biostatistics and Databases Program, Kirby Institute
Ms Awachana Jiamsakul - Statistician- Biostatistics and Databases Program, Kirby Institute
Abstract:
The TREAT Asia adult HIV cohorts consist of two drug resistance cohorts (TASER-S and TASER-M) and the ongoing observational cohort (TAHOD). TASER-S was a cross-sectional study evaluating drug resistance in treatment-naïve recently infected individuals, while TASER-M was a longitudinal cohort aimed at monitoring drug resistance in treatment naïve individuals initiating treatment and those who failed first-line ART. Pediatric observational HIV data is also collected by TREAT Asia via the TREAT Asia pediatric HIV Observational Database (TApHOD).
David Boettiger: As the scale up of ART continues in Asia, it is becoming increasingly important to monitor and evaluate the use of available regimens and resources. This is especially true for HIV-infected individuals at high risk of poor outcomes on ART. This talk will describe ART use in second-line patients enrolled in TAHOD, perinatally infected adolescents in TApHOD, and children with severe malnutrition enrolled in TApHOD. Emphasis will be placed on the programmatic changes most likely help optimise ART use in these populations.
Awachana Jiamsakul: Among recently HIV infected individuals, the prevalence of transmitted drug resistance mutations in Asian countries after the scale up of ART have found to vary but remained below the WHO upper limit threshold of 15%. Acquired drug resistance develop after ART exposure and have been found in high proportions (up to 95%) of patients failing first-line ART in Asia, where the standard first-line regimen normally consists of NRTI+NNRTI combination. In this talk, we will examine proportions of drug resistance mutations in recently infected individuals and the development of multi-NRTI resistance in patients failing ART and their subsequent virological response. We will further investigate suboptimal adherence within the TASER-M cohort and their associated predictors.
Bio:
David Boettiger is a biostatistician and PhD candidate with the Biostatistics and Databases Program. His doctoral research is focused on the optimal use of adult and pediatric ART in Asia, although, he also has a strong interest in the treatment of HCV/HIV and HBV/HIV co-infection. David is a trained pharmacist and has previously worked as a scientific advisor for various pharmaceutical companies. He obtained his Bachelor of Biomedical Science and Master of Pharmacy from the University of Newcastle, Australia and Master of Epidemiology from the University of Utrecht, The Netherlands.
Awachana (Am) Jiamsakul is currently completing her PhD with the Biostatistics and Databases Program, focusing on ART adherence and drug resistance within the TREAT Asia cohorts. Born in Bangkok, Thailand, Am moved to Australia just after the Bicentenary celebrations. Am obtained a Bachelor of Science majoring in Pharmacology and Statistics from the University of Sydney, and Master of Statistics from UNSW. She has previously worked in the pharmaceutical industry and prior to joining the Kirby as a Data Analyst at St Vincent’s Hospital, Bone Marrow Transplant research unit.